OXP Group Plc develops advanced yet practical pharmaceutical technologies to enable reformulation that adds value to off patent and soon to be off patent drugs. The company does not manufacture or sell its own pharmaceutical products but instead seeks to license its technologies to a network of partners, mainly leading pharmaceutical companies with Rx and OTC branded portfolios. These partners use our technologies to reposition their products helping them sustain market share and profitability by delivering improved health outcomes and/or clinical profiles via reformulated versions of the same API. http://www.oxfordpharmascience.com/
Oxford Pharmascience (LON:OXP) has successfully completed the formulation development for its Safestat formulations of Atorvastatin and Simvastatin, the leading generic statin drugs.